Risks and limits of Abnehmspritze Genetik

The question about risks and limits of genetic testing for weight loss injections (GLP-1 agonists like semaglutide) is timely. Current commercial DNA tests claiming to predict individual response to these drugs are based on limited evidence. While some studies have identified genetic variants (e.g., in GLP1R, TCF7L2) that may modestly influence weight loss on GLP-1 agonists, effect sizes are small and findings are not consistently replicated. Clinical decisions rely on baseline weight, metabolic health, and lifestyle – not genetic markers. Risks of such tests include false reassurance, neglect of lifestyle factors, and substitution of medical supervision. GLP-1 drugs are prescription-only and carry side effects (nausea, pancreatitis, gallstones). A genetic test cannot predict these adverse events. The evidence level is 'mixed': mechanistic and some human studies exist, but no validated clinical algorithms. Consumers should be wary of marketing that overstates genetic precision. Medical consultation and individual risk-benefit assessment remain essential.